Takeda: Diabetes Mellitus trials

The registry lists 109 Diabetes Mellitus studies with Takeda as lead sponsor. 0 are open to participants now and 70 have results posted.

Phase 1 3Phase 2 21Phase 3 58Phase 4 14No phase 20(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in KoreaCompletedNCT04980014Results posted
• Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"CompletedNCT04285983Results posted
• Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"CompletedNCT03555591Results posted
• Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"CompletedNCT03555565Results posted
• A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)CompletedNCT03268941Phase 2Results posted
• Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes MellitusCompletedNCT03231709Phase 4Results posted
• Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes MellitusCompletedNCT03014479Phase 4Results posted
• Epidemiologic Study Of Diabetes And Cancer RiskCompletedNCT02958995Results posted
• Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.CompletedNCT02958956Results posted
• Phase 3 Alogliptin Pediatric StudyCompletedNCT02856113Phase 3Results posted
• An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes MellitusCompletedNCT02771093Phase 4Results posted
• An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2CompletedNCT02756832Results posted
• Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in AsiaCompletedNCT02517866Phase 4Results posted
• A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal DiseaseCompletedNCT02512068Phase 3Results posted
• A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and MicroalbuminuriaCompletedNCT02332824Phase 2Results posted
• A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT02324569Phase 3Results posted
• Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"CompletedNCT02221284Results posted
• Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to PioglitazoneCompletedNCT02098746Results posted
• Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes MellitusCompletedNCT02098733Results posted
• A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-RCompletedNCT02079805Phase 4Results posted
• Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 DiabetesCompletedNCT02049814Phase 4Results posted
• Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes MellitusCompletedNCT02024971Results posted
• Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"CompletedNCT02002975Results posted
• Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes MellitusCompletedNCT01990300Results posted
• Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral TherapyCompletedNCT01972724Phase 4Results posted
• Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With BiguanidesCompletedNCT01964976Results posted
• Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes MellitusCompletedNCT01964963Results posted
• Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With SulfonylureaCompletedNCT01964950Results posted
• Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"CompletedNCT01945242Results posted
• Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"CompletedNCT01945216Results posted
• Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 DiabetesCompletedNCT01890122Phase 3Results posted
• Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 DiabetesTerminatedNCT01834274Phase 3Results posted
• Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 DiabetesTerminatedNCT01829477Phase 3Results posted
• TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 DiabetesTerminatedNCT01829464Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 DiabetesTerminatedNCT01647542Phase 3Results posted
• Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II DiabetesCompletedNCT01637935Results posted
• Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseTerminatedNCT01609582Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and DiabetesTerminatedNCT01496430Phase 3Results posted
• Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesTerminatedNCT01481116Phase 3Results posted
• Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 DiabetesCompletedNCT01456195Phase 3Results posted
• Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 DiabetesCompletedNCT01456130Phase 3Results posted
• Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in JapanCompletedNCT01318135Phase 2/3Results posted
• Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in JapanCompletedNCT01318122Phase 2/3Results posted
• Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in JapanCompletedNCT01318109Phase 2/3Results posted
• Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in JapanCompletedNCT01318083Phase 2/3Results posted
• Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in JapanCompletedNCT01318070Phase 2/3Results posted
• Efficacy and Safety of Alogliptin in Participants With Type 2 DiabetesCompletedNCT01289119Phase 3Results posted
• Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanCompletedNCT01263509Phase 2/3Results posted
• Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in JapanCompletedNCT01263496Phase 2Results posted
• Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanCompletedNCT01263483Phase 2/3Results posted
• Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in JapanCompletedNCT01263470Phase 2Results posted
• Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 DiabetesCompletedNCT01023581Phase 3Results posted
• Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeCompletedNCT00968708Phase 3Results posted
• Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes MellitusCompletedNCT00957268Phase 1Results posted
• Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusCompletedNCT00856284Phase 3Results posted
• Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.CompletedNCT00770653Phase 3Results posted
• Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.CompletedNCT00755846Phase 2Results posted
• Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.CompletedNCT00727857Phase 3Results posted
• Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly DiabeticsCompletedNCT00707993Phase 3Results posted
• Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.CompletedNCT00655863Phase 3Results posted
• Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00432276Phase 3Results posted
• Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes MellitusCompletedNCT00395512Phase 3Results posted
• Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.CompletedNCT00328627Phase 3Results posted
• Long-term Safety of Alogliptin in Patients With Type 2 Diabetes MellitusCompletedNCT00306384Phase 3Results posted
• Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00286494Phase 3Results posted
• Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.CompletedNCT00286468Phase 3Results posted
• Efficacy and Safety of Alogliptin in Subjects With Type 2 DiabetesCompletedNCT00286455Phase 3Results posted
• Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes MellitusCompletedNCT00286442Phase 3Results posted
• Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.CompletedNCT00286429Phase 3Results posted
• Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes MellitusCompletedNCT00225277Phase 3Results posted
• Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes MellitusWithdrawnNCT03042325Phase 4
• A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322CompletedNCT01686711Phase 4
• Study of Combination Therapy With SYR-322CompletedNCT01521962Phase 3
• Open-label Study of TAK-875CompletedNCT01433419Phase 3
• Long-term Study of TAK-875CompletedNCT01433406Phase 3
• Double-blind Comparative Study of TAK-875CompletedNCT01433393Phase 3
• Long-term Study of SYR-472CompletedNCT01431807Phase 3
• Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes MellitusCompletedNCT01414920Phase 2
• TAK-329 Glucose Clamp StudyCompletedNCT01311076Phase 1
• Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 DiabetesTerminatedNCT01124656Phase 3
• Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes MellitusCompletedNCT01007097Phase 2
• Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 DiabetesCompletedNCT00949091Phase 1
• Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 DiabetesCompletedNCT00772174Phase 3
• Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.CompletedNCT00770952Phase 3
• Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.CompletedNCT00770835Phase 4
• Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.CompletedNCT00770640Phase 2
• Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.CompletedNCT00770445Phase 4
• Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes MellitusTerminatedNCT00763347Phase 2
• Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusCompletedNCT00763022Phase 3
• Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.TerminatedNCT00762957Phase 3
• Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes MellitusCompletedNCT00762736Phase 2
• Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusTerminatedNCT00762684Phase 3
• Study of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusTerminatedNCT00762190Phase 3
• Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes MellitusTerminatedNCT00762112Phase 3
• Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes MellitusCompletedNCT00760344Phase 2
• Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.TerminatedNCT00759720Phase 3
• Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 DiabetesCompletedNCT00754403Phase 4
• Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes MellitusTerminatedNCT00722917Phase 2
• Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With InsulinCompletedNCT00676260Phase 2
• Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.CompletedNCT00672919Phase 4